Kyverna rings the Nasdaq opening bell on Feb. 8, 2024 (Lei Lei Wu for Endpoints News)
February 8, 2024 04:08 PM EST
Cell/Gene Tx

Kyver­na surges af­ter IPO, and CEO lays out plans for cell ther­a­py in im­mune dis­eases

Kyle LaHucik

Senior Reporter

Kyver­na Ther­a­peu­tics start­ed its first day as a pub­lic biotech on a strong note, with its shares $KYTX ris­ing more than 50% Thurs­day af­ter­noon af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times